Lung cancer is the second most common cancer among men and women in the United States and the leading cause of cancerrelated mortality (1) . Consequently, even small disparities in the incidence, mortality, and burden of this disease affect many individuals. The U.S. government has prioritized studying and remedying disparities in cancer care (2) , and it is important to evaluate the reasons underlying these disparities.
Differences in insurance status may contribute directly to disparate cancer outcomes. In addition, differences in race, ethnicity, income, education, and other factors that are related to insurance status may also have an effect on processes and outcomes of care (1, (3) (4) (5) (6) . The insurance system in the United States is fragmented between public and private providers and is incomplete, with an estimated 20% of adults under 65 who are uninsured (7) . Documenting differences in lung cancer care based on insurance status is important for planners and providers of health care, given that policies can be designed and implemented to reduce disparities.
Our objective was to systematically review and critically appraise all available studies that have examined the association between insurance status and practices and outcomes in patients with lung cancer.
METHODS Study Identification
We followed the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines in the development of this systematic review (8) . Systematic methods were used to identify relevant studies, assess study eligibility for inclusion, and evaluate study quality (9, 10) . We attempted to find all published studies examining care and outcomes for patients with and/or at risk for lung cancer associated with individual insurance status.
One investigator (CGS), with the help of a professional medical librarian, searched the online databases of MEDLINE, ProQuest (which includes dissertations), EBSCOHost (which includes CINAHL), CSA Illumina, EMBASE, and ISI Web of Knowledge, from January 1970 to November 6, 2008 (some manuscripts were e-published and listed in the database but not published in print form until after November 2008). We used the most general search terms to be all-inclusive. The specific terms entered for the searches are included (see Part A of the online supplement). Articles that were repeated in different database searches were not tallied separately. We captured additional articles by reviewing reference lists from identified studies and pertinent review articles.
Study Eligibility
Two investigators (either C.G.S./D.H.A. or C.G.S./M.K.G.) independently assessed original research studies for eligibility according to predefined criteria (Part B of the online supplement), with disagreements resolved by discussion. We included studies that analyzed aspects of care for patients with and/or at risk of lung cancer according to differences in individual insurance status. Studies that used nonindividual measures of insurance status such as geographic correlates were excluded. Studies that enrolled patients with diagnoses other than lung cancer were eligible for inclusion if the outcomes from the patients with lung cancer were reported separately or if patients with lung cancer constituted at least 80% of the sample. As the insurance system in the United States was the focus of the analysis, only studies of patients in the United States were eligible.
Data Abstraction
We abstracted data about demographic characteristics, insurance status, specific care outcomes, statistical tests and significance, and adjustment for confounders. We also collected data about how the outcomes and insurance status were recorded. We divided care outcomes into the following categories: incidence, stage at diagnosis, mortality, access to care, and delivery of care.
The delivery of care category was broken into subcategories related to procedures and treatments, hospice care, and other.
Study Quality
To measure study quality we developed a 16-item inventory. These items included measures of cohort assembly, exposure measurement, outcome measurement, adjustment for confounding, statistical analysis, funding, and conflict of interest disclosure. Each question was graded either ''Yes,'' ''No,'' ''Unsure,'' or ''Not applicable'' by one investigator (C.G.S.). Individual questions are listed in Figure 2 and quality was graded as the total number of ''Yes'' responses over the possible number. Many studies were cross-sectional, so the question regarding appropriate follow-up was not relevant.
Statistical Analysis
Median values and ranges for summary statistics are reported based on information provided by each of the primary study authors. We did not attempt to pool data across studies because there was substantial heterogeneity in exposure and outcome measures, and few studies provided raw data that would be necessary for quantitative synthesis.
RESULTS
We identified 3,798 potentially relevant citations, of which 3,739 were judged not to be relevant after reviewing their title and abstract. Twenty-three of 59 remaining manuscripts were deemed eligible using our predefined inclusion criteria (Part B of the online supplement) following full-text review (Figure 1 ). One article was excluded after we determined that two articles reported the same results (11, 12) , 27 were excluded because they did not compare groups defined by insurance status, 5 were excluded because they did not include enough lung cancer cases, and 3 were excluded because they were not research studies ( Figure 1 ). The characteristics of the studies that were included are listed chronologically in Table 1. Table 2 lists the studies, outcomes measured, insurance status, and results. 
Study Quality
In general, study quality was very good. Twelve of 16 quality criteria were met by more than 75% of the studies. Most studies used a cross-sectional or cohort design. Twenty-one of 23 studies used registry data to analyze large populations and employed appropriate methods to characterize both the outcomes of interest and insurance status. Seventy-three percent of studies adjusted for confounders, though many were not able to adjust for individual smoking behaviors, comorbid conditions, socioeconomic status, and education. Seventy percent provided information about funding sources, 39% included a conflict of interest statement, and very few (4%) reported the results of power calculations. Figure 2 shows the percentage of studies that met each pre-specified quality measure.
Incidence
Two studies examined the association between insurance status and lung cancer incidence rates. Using data from Michigan, Bradley and coworkers compared Medicaid-to non-Medicaidinsured patients stratified by age and sex, and found that lung cancer incidence rates were higher for all groups of patients with Medicaid (13) . In a similar study, patients with Medicare alone had consistently lower incidence rates compared with patients with Medicaid/Medicare, but the incidence rates were similar when the comparison group was restricted to patients covered by Medicaid for more than 12 months before diagnosis (14) ( Table  2) . Neither study was able to adjust for smoking behaviors.
Stage at Diagnosis
Several studies identified associations between insurance status and lung cancer stage. Bradley and colleagues (13) found that advanced-stage disease was more common in Medicaid patients younger than 65 years of age compared with patients younger than 65 with non-Medicaid insurance. In another study of patients with lung cancer between 25 and 64 years of age who were included in the Michigan Medicaid and Cancer Registries, those who received Medicaid after being diagnosed with lung cancer were more likely to have advanced-stage disease at the time of diagnosis (15) . There was no significant difference between patients who had Medicaid insurance at the time of diagnosis compared with non-Medicaid patients. A similar study limited to patients over 65 years of age showed that compared with patients only on Medicare, Medicaid patients were more likely to have unknown, regional, or distant stage (16) ( Table 2) . A cross-sectional study of the U.S. National Cancer Database of almost 700,000 patients with lung cancer found that compared with patients with private insurance, those with Medicaid or no insurance were more likely to be diagnosed with more advanced-stage disease (17) . The risk for Medicare patients was similar to that of patients with private insurance. In another study of patients with Medicare Disability insurance, there were no differences in stage comparing a fee-for-service (FFS) status with health maintenance organization (HMO) or a combination insurance status (18) . Finally, a study of nonelderly * The Quality Score lists the total number of ''Yes'' answers to the quality questions over the total possible score. † The focus of this study was to compare changes in care outcomes after a diagnosis-related group cost assessment was changed. Only outcomes looking at the postchange outcomes are presented in Table 2 .
‡ Survival outcomes not shown in Table 2 due to space considerations. Table 2) .
Mortality
Several studies evaluated the association of insurance status with mortality. Greenberg and coworkers examined all-cause mortality 3 to 6 years after a lung cancer diagnosis, finding no association with insurance status (20) . In contrast, Bradley and colleagues showed that Medicaid recipients had worse stagespecific and overall survival than Medicare patients, except for stage IV patients who were less than 65 years of age, for whom the difference was not statistically significant (13) ( Table 2) . Likewise, Bradley and coworkers found that among patients with lung cancer less than 65 years old, Medicaid coverage was associated with higher mortality for men and women diagnosed with both local and more advanced-stage disease compared with non-Medicaid insurance (21) . In another study, Bradley and colleagues examined mortality in elderly patients with local or regional non-small cell lung cancer (NSCLC), finding that Medicaid/Medicare status was associated with higher all-cause mortality compared with Medicare for patients who underwent surgical resection. There were no differences among patients who did not undergo resection or in perioperative mortality (22) . Finally, Bradley and coworkers showed that among patients over 65 with all stages of lung cancer, Medicaid patients had higher risks of dying the same month of diagnosis (16) ( Table 2) . A study from the Kentucky Cancer Registry showed that patients with lung cancer without private health insurance were more likely to die within 3 years of diagnosis after adjusting for stage (23) . Shugarman and colleagues, using a SEER-Medicare database and adjusting for stage, found a higher hazard ratio for overall mortality for patients with combined Medicare/ Medicaid compared with Medicare (24). Cheung and coworkers used a state cancer database of patients undergoing curativeintent surgical resection that showed increased mortality associated with no insurance or Medicaid insurance compared with private insurance (25) . Roetzheim and colleagues examined all-cause and lung cancer-specific mortality in patients with lung cancer with Medicare-Disability insurance, finding that mixed FFS/HMO insurance compared with an FFS plan was associated with increased all-cause mortality but no difference in lung cancer mortality (18) . There was no difference between HMO-only and FFS-only plans. In contrast, Du and coworkers performed a single-center case-control study that showed no difference in overall 1-year mortality comparing patients with commercial insurance to other insurance statuses (26) ( Table 2 ).
Access to Care
Several studies evaluated the association of insurance status with measures of access to care. Liu and colleagues used a state hospital discharge database to show that among patients who underwent surgical resection for NSCLC, patients with Medicare were more likely to be treated at high-volume hospitals (defined as the 20% of hospitals performing the most procedures) compared with patients with Medicaid, private insurance, and those who were uninsured (27) . Neighbors and coworkers, using the Nationwide Inpatient Sample Database, found that compared with patients with private insurance, patients with Medicaid or other insurance (included self-pay, no-charge, and ''other,'' but not Medicare) were less likely to receive treatment at a hospital that performs more than the median number of resections (28) . Greenberg and colleagues used the New Hampshire-Vermont Central Tumor Registry to show that privately insured patients were less likely than patients with other insurance to be diagnosed at a university cancer center, but there was no difference in treatment location (29) ( Table 2) .
Delivery of Care
Procedures and Treatments. Several studies explored the association between insurance status and receipt of procedures and treatments. Greenberg and coworkers found that private compared with other insurance status was associated with increased rates of surgery and radiation (20) . Roetzheim and colleagues showed that patients with Medicare-Disability insurance enrolled in mixed FFS/HMO plans were more likely to receive surgery compared with patients with only FFS plans (18). Esnaola and coworkers used a state cancer registry to show that among patients with localized NSCLC, those with commercial insurance were more likely to receive surgery than patients with noncommercial insurance (30) . Bradley and colleagues used a state cancer registry to show that patients over 65 years old with Medicaid/Medicare insurance were less likely to receive resection, more likely to receive radiation, and equally likely to receive chemotherapy compared with patients with only Medicare insurance (22) (Table 2) .
Potosky and coworkers examined the records of almost 900 randomly identified patients with NSCLC from a SEER cancer registry (31) . They found that in general, patients with only private insurance had lower rates of recommended therapy compared with patients with either public plus private insurance or public insurance alone. Using a SEER database, Harlan and colleagues found that patients with no insurance were more likely and those with nonprivate insurance were less likely than those with private insurance to receive National Cancer Care Network (NCCN)-guideline concordant care (32) ( Table 2) .
Hospice Care. McCarthy and coworkers (12) found more frequent and longer hospice enrollment for patients with Medicare-HMO plans compared with Medicare-FFS plans (see Table 2 ).
Other. Two studies examined the association of costs of care with insurance status for patients with lung cancer and one study evaluated transferring care from a HMO to a FFS plan. In patients with Stage II-IV NSCLC, Du and colleagues found no difference in the cost at 1 year between patients who did and did not have commercial insurance (26) . In a dissertation, Spraberry found that compared with non-Medicare patients with lung cancer, Medicare recipients had shorter hospital lengths of stay after surgery, longer stays for a medical hospitalization, and decreased charges for both (33) . Using a combined Surveillance Epidemiology End Results (SEER)-Medicare database to look at transfer of care from a Medicare HMO plan to a Medicare FFS plan, Elkin and coworkers found that HMO patients with lung cancer were more likely to switch than cancer-free control patients (34) ( Table 2 ).
DISCUSSION
In this review, we found that patients with lung cancer with Medicaid insurance had poorer outcomes, including higher incidence rates, worse stage at diagnosis, and poorer survival even after adjustment for stage of diagnoses. Although we were not able to pool the results of these studies, the magnitude of the associations between Medicaid and both stage of diagnosis and mortality were similar. Patients with Medicaid were diagnosed with more advanced disease and were more likely to die the same month of diagnosis. Furthermore, the mortality of Medicaid patients was higher; some of the survival difference may be secondary to lead-time bias, since stage of diagnosis was worse for patients with Medicaid. However, this bias is unlikely to explain all the mortality difference, since several studies found higher rates of surgery and radiation therapy for patients with private and combined insurances. This mortality decrement may persist despite the findings from two studies that found patients with private insurance were less likely to receive guideline-concordant care.
Patients with Medicare appeared to have outcomes that were similar to patients with private insurance. Only two studies directly examined outcomes in patients with lung cancer with no insurance, finding that uninsured were more likely to be diagnosed with advanced-stage disease (17) and to die (23) . Bradley and colleagues speculated that many or most patients who received Medicaid shortly before or after they received a lung cancer diagnosis were probably uninsured previously. If so, these studies add to the evidence that uninsured patients may be diagnosed with later stages of lung cancer and have an increased hazard of death (15, 16, 21) .
Many studies did not adjust for patient-level characteristics such as smoking behaviors, comorbidities, socioeconomic status, and education. Several studies attempted to adjust for differences in groups by using geographic level variables, but this is unlikely to eliminate residual confounding. Importantly, it has been shown that patients with Medicaid are more likely to be current smokers (35) , less likely to be offered comprehensive smoking cessation treatment (36) , and less likely to receive cessation pharmacotherapy (37, 38) . Current smoking at the time of surgical resection for stage I to IIIA NSCLC has been associated with an increased risk of death (39) , as has active smoking at the time of receipt of chemotherapy (40) . Thus, active smoking may confound the observed associations between Medicaid status and care outcomes, especially as they relate to incidence and mortality.
The mechanisms underlying care disparities for patients without insurance and for those who receive Medicaid are unclear but probably multifactorial (6, 41) . There are likely patient-related factors, such as individual differences in health behaviors such as smoking, income, education, and comorbidities. Others may stem from a differential ability to interact with the healthcare system, differences in the care provided by institutions that serve Medicaid and uninsured patients, and less access to better-quality care. Our review indicates that some of these latter mechanisms may be important based on studies that show differential rates of receiving guideline-concordant care (31, 32) , receiving care at a university cancer center (29) , receipt of surgery or radiation therapy (20) , and receipt of care at highvolume centers (27, 28) . Although uninsured patients and those with Medicaid may be more likely to be treated at certain centers, no studies directly adjusted for center-level effects, so we cannot determine their role on the assessed outcomes (42) .
Many of the included studies are likely generalizable to the adult population of the United States, though the generalizability of the studies that examined patients younger than 65 years is unclear, since this age group makes up a minority of patients with lung cancer (1) .
In summary, we found that compared with other groups, patients with Medicaid or no insurance had higher lung cancer incidence rates, more advanced stage at diagnosis, and higher stage-specific and overall mortality rates. In addition, they were less likely to receive surgery or radiation, or to receive treatment at a high-volume center. Some of the disparities may be secondary to residual confounding from smoking, comorbidities, and other health behaviors, but available data suggest that patients with lung cancer without insurance do poorly because access to care is limited and they present with more advanced disease that is less amenable to treatment. Interestingly, patients with no insurance were more likely to receive guidelineconcordant care than those with private insurance, suggesting that worse survival in these patients may be due to poor access, and not to receipt of poor quality care once they enter the healthcare system. More research focusing on specific aspects of access and delivery of care may help to clarify the underlying mechanisms that contribute to important lung cancer care disparities. Practicing physicians, quality managers, researchers, and policy makers should be cognizant of these disparities when attempting to improve care for patients with lung cancer. Overall, the preponderance of the evidence suggests that improving access to care by expanding health insurance coverage would result in better outcomes for patients with lung cancer.
